Table 1.
Comparison of demographic characteristics between early-onset group and late-onset group
| All (n = 64) | Early-onset group (n = 32) | Late-onset group (n = 32) | χ2/t | P | |
|---|---|---|---|---|---|
| Sex | |||||
| Male, n (%) | 34 (53.1) | 18 (56.3) | 16 (50) | 0.251 | 0.616 |
| Female, n (%) | 30 (46.9) | 14 (43.7) | 16 (50) | ||
| Age, (years), Mean ± SD | 46.22 ± 13.90 | 40.53 ± 15.39 | 51.91 ± 9.42 | 3.566 | 0.001* |
| Age onset, (years), Mean ± SD | 25.59 ± 17.87 | 9.78 ± 2.62 | 41.38 ± 11.26 | 15.46 | 0.000* |
| BMI, (kg/m2), Mean ± SD | 23.97 ± 3.50 | 24.14 ± 3.35 | 23.82 ± 3.66 | 0.353 | 0.725 |
| Length of hospital stay, (days), Mean ± SD | 7.41 ± 2.57 | 7.75 ± 2.77 | 7.06 ± 2.34 | 1.072 | 0.288 |
| Asthma duration, (months), Mean ± SD | 221.45 ± 186.14 | 309.06 ± 199.28 | 133.84 ± 121.87 | 4.243 | 0.000* |
| Smoking history | |||||
| Yes, no quit, n (%) | 9 (14.1) | 3 (9.4) | 6 (18.8) | 1.956 | 0.376 |
| Yes, quit, n (%) | 10 (15.6) | 4 (12.5) | 6 (18.8) | ||
| No, n (%) | 45 (70.3) | 25 (78.1) | 20 (62.4) | ||
| Hormone medication history, n (%) | 19 (29.7) | 13 (40.6) | 6 (18.8) | 3.668 | 0.055 |
| Medication use, n (%) | |||||
| High dose ICS | 54 (84.4) | 25 (78.1) | 29 (90.6) | 1.896 | 0.168 |
| Family history of asthma, n (%) | 25 (39.1) | 17 (53.1) | 8 (25.0) | 5.317 | 0.021* |
| ACT score, Median (Q1, Q3) | 16.0 (14.0, 19.0) | 16.0 (14.0, 18.0) | 15.5 (14.0, 19.0) | 0.061 | 0.951 |
| Lung function | |||||
| FEV1, (L), Mean ± SD | 2.03 ± 0.84 | 2.21 ± 1.04 | 1.87 ± 0.58 | 1.544 | 0.130 |
| FEV1%pred, (%), Mean ± SD | 68.43 ± 20.55 | 68.13 ± 23.69 | 68.70 ± 17.61 | 0.108 | 0.915 |
| FVC%pred, (%), Mean ± SD | 87.73 ± 17.29 | 84.43 ± 18.63 | 90.71 ± 15.67 | 1.429 | 0.158 |
| FEV1/FVC, (%), Mean ± SD | 63.87 ± 11.16 | 65.90 ± 13.37 | 62.03 ± 8.50 | 1.364 | 0.178 |
| MEF50%, (%), Mean ± SD | 39.05 ± 27.13 | 46.19 ± 34.87 | 32.58 ± 15.36 | 2.004 | 0.050 |
| MEF25%, (%), Mean ± SD | 29.69 ± 19.14 | 35.01 ± 25.21 | 24.86 ± 9.22 | 2.046 | 0.048* |
| MMEF75/25%, (%), Mean ± SD | 34.78 ± 23.38 | 41.11 ± 30.35 | 29.04 ± 12.42 | 2.067 | 0.043* |
| Complications | |||||
| Sinusitis, n (%) | 28 (43.8) | 14 (43.8) | 14 (43.8) | 0.000 | 1.000 |
| Allergic rhinitis, n (%) | 22 (34.4) | 13 (40.6) | 9 (28.1) | 1.108 | 0.292 |
| Atopy, n (%) | 37 (57.8) | 21 (65.6) | 16 (50.0) | 1.602 | 0.206 |
| Allergens | |||||
| Medicine, n (%) | 14 (21.9) | 9 (28.1) | 5 (15.6) | 1.463 | 0.226 |
| Dust mites, n (%) | 24 (37.5) | 17 (53.1) | 7 (21.9) | 6.229 | 0.013* |
| Blattellagermanica, n (%) | 22 (34.4) | 13 (40.6) | 9 (28.1) | 0.931 | 0.335 |
| Aspergillus fumigatus, n (%) | 9 (14.1) | 5 (15.6) | 4 (12.5) | 0.000 | 1.000 |
| Shrimp, n (%) | 17 (26.6) | 10 (31.3) | 7 (21.9) | 0.601 | 0.438 |
| Dermatophagoides farinae, n (%) | 20 (31.3) | 14 (43.8) | 6 (18.8) | 4.325 | 0.038* |
| Total IgE, (U/L), Median (Q1, Q3) | 254.0 (86.39, 602.35) | 319.7 (156.0, 607.8) | 179.7 (69.74, 646.5) | 0.969 | 0.332 |
SD: standard deviation; BMI: body mass index; ACT: asthma control test; Q1: quartile 1; Q3: quartile 3; ICS: Inhaled glucocorticoid; FEV1: forced expiratory volume in 1 s; FEV1%pred: FEV1 percentage of predicted; FVC: forced vital capacity; FVC%pred: FVC percentage of predicted; MEF: maximum expiratory flow; MMEF: maximal mid-expiratory flow
*Represent P < 0.05, suggest statistical significance